- Home
- SAFE vs NRIX Comparison
SAFE vs NRIX Comparison
Compare SAFE & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFE
- NRIX
- Stock Information
- Founded
- SAFE 2016
- NRIX 2009
- Country
- SAFE United States
- NRIX United States
- Employees
- SAFE N/A
- NRIX N/A
- Industry
- SAFE Real Estate Investment Trusts
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- SAFE Real Estate
- NRIX Health Care
- Exchange
- SAFE Nasdaq
- NRIX Nasdaq
- Market Cap
- SAFE 1.2B
- NRIX 1.4B
- IPO Year
- SAFE 2017
- NRIX 2020
- Fundamental
- Price
- SAFE $16.83
- NRIX $16.87
- Analyst Decision
- SAFE Buy
- NRIX Strong Buy
- Analyst Count
- SAFE 9
- NRIX 16
- Target Price
- SAFE $25.22
- NRIX $31.75
- AVG Volume (30 Days)
- SAFE 421.1K
- NRIX 658.9K
- Earning Date
- SAFE 02-05-2025
- NRIX 04-09-2025
- Dividend Yield
- SAFE 4.21%
- NRIX N/A
- EPS Growth
- SAFE N/A
- NRIX N/A
- EPS
- SAFE 1.48
- NRIX N/A
- Revenue
- SAFE $388,662,000.00
- NRIX $54,549,000.00
- Revenue This Year
- SAFE N/A
- NRIX $3.28
- Revenue Next Year
- SAFE $8.16
- NRIX $6.73
- P/E Ratio
- SAFE $11.37
- NRIX N/A
- Revenue Growth
- SAFE 3.15
- NRIX N/A
- 52 Week Low
- SAFE $15.55
- NRIX $10.17
- 52 Week High
- SAFE $28.80
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- SAFE 46.13
- NRIX 35.92
- Support Level
- SAFE $16.63
- NRIX $16.56
- Resistance Level
- SAFE $17.85
- NRIX $18.07
- Average True Range (ATR)
- SAFE 0.58
- NRIX 0.91
- MACD
- SAFE 0.07
- NRIX -0.13
- Stochastic Oscillator
- SAFE 50.47
- NRIX 9.95
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.